Deal Secures Supply of Essential Biologicals

Germany-based BioNTech (Mainz), a company focused on supplying critical raw materials for the manufacturing of precise immunotherapy vaccine candidates, has signed a multi-year agreement with Thermo Fisher Scientific for the supply of nucleotides, enzymes and other materials to support BioNTech's messenger RNA (mRNA) manufacturing platform. The four-year, nonexclusive licensing and supply agreement gives BioNTech rights to use Thermo Fisher's technologies as part of its clinical and commercial manufacturing processes.

"Our portfolio of molecular biology products is now enabling development and commercialisation of multiple individualised therapies and other advanced medicines and we continue to expand our capabilities to meet increasing demand," said Gianluca Pettiti, president, biosciences, Thermo Fisher Scientific. "We share BioNTech's commitment to deliver life-saving therapies to patients faster and we look forward to supporting them through clinical trials and post-approval production."

"The relationship with Thermo Fisher Scientific secures our access to customised material essential for the manufacturing and commercialisation of our RNA-based product candidates," said Ugur Sahin, managing director, co-founder and CEO of BioNTech. "In addition, as a life science services leader, Thermo Fisher can also deliver reagents at the scale needed to expand our manufacturing capacities."

No other terms from this transaction were disclosed.